RTC
KRYS icon

Riverview Trust Company’s Krystal Biotech KRYS Stock Holding History

Riverview Trust Company’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3
Closed -$470 – 731
2024
Q4 		$470 Buy
+3
New +$532 ﹤0.01% 803

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Riverview Trust Company's KRYS Position: Q1 2025 in Review

Riverview Trust Company sold out of Krystal Biotech (KRYS) in Q1 2025, closing a stake of 3 shares — an estimated $470 sold.

Riverview Trust Company first reported a position in KRYS in Q4 2024 and held it in 1 quarter. The position peaked at $470 in Q4 2024. 299 funds tracked by Wall St. Rank hold KRYS as of Q1 2025.

  • Riverview Trust Company reported no remaining Krystal Biotech position as of Q1 2025 after selling out during the quarter.
  • Riverview Trust Company sold 3 Krystal Biotech shares in Q1 2025, an estimated $470.
  • Riverview Trust Company first reported a position in Krystal Biotech in Q4 2024 and held it in 1 quarter.
  • Riverview Trust Company's Krystal Biotech position peaked at $470 in Q4 2024.
  • 299 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2025.

Based on Riverview Trust Company's 13F filing for Q1 2025, filed 11 Apr 2025.